Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy

Although oncolytic viruses are currently being evaluated for cancer treatment in clinical trials, systemic administration is hindered by many factors that prevent them from reaching the tumor cells. When administered systemically, mesenchymal stem cells (MSCs) target tumors, and therefore constitute...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Chun-Te, Wu, Mei-Hsuan, Chen, Ming-Jen, Lin, Shih-Pei, Yen, Yu-Ting, Hung, Shih-Chieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153168/
https://www.ncbi.nlm.nih.gov/pubmed/34068264
http://dx.doi.org/10.3390/biomedicines9050548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153168/
https://www.ncbi.nlm.nih.gov/pubmed/34068264
http://dx.doi.org/10.3390/biomedicines9050548

Ejemplares similares